Key result
Low molecular weight heparin PK 10169 retains standard heparin's ability to release lipoprotein and hepatic lipase activity after intravenous injection despite reduced anticoagulant capacity.
Key points are not available for this paper at this time.
Hypothesis-generating for LMWH lipase modulation with less anticoagulation; leaves open clinical relevance pending in vivo data.
A low molecular weight heparin (MW 4000-6000), PK 10169 (Pharmuka), with much reduced anticoagulant in vitro capacity, retains the properties of the standard heparin in releasing lipoprotein lipase and hepatic lipase activity after being injected intravenously.
No takes yet. Share an insight, caveat, or question.
Etienne et al. (1983) studied this question. Low molecular weight heparin PK 10169 retains standard heparin's ability to release lipoprotein and hepatic lipase activity after intravenous injection despite reduced anticoagulant capacity.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: